Entera Bio Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.34next fiscal year
Monitoring Framework
Key Performance Indicators
EB613 Phase 3 Trial Initiation QuarterlyTarget: Initiation of multinational Phase 3 trial in late 2026
EB612 IND Application Filing QuarterlyTarget: IND filing with the FDA in late 2026
Cash Runway Quarterly20.4MTarget: Support operations through Q1 2027
Watch Items
- FDA Feedback on Streamlined EB613 Phase 3 ProtocolTrigger: Official FDA response regarding the 750-patient trial design and percentage change in total hip BMD at 12 monthsAction: Review protocol adjustments or proceed directly to trial site activation if aligned
- EB612 Preclinical and IND-Enabling ProgressTrigger: Completion of IND-enabling studies for oral LA-PTH(1-34) tabletAction: Prepare and submit IND application in late 2026 in partnership with OPKO Health
Research as of 20 Jun 2026